Get the Stockscreener App
8.205
26.68%
1.795
Meiragtx Holdings Plc stock is traded at $8.205, with a volume of 3.44M.
It is up +26.68% in the last 24 hours and up +23.03% over the past month.
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
See More
Previous Close:
$6.41
Open:
$7.73
24h Volume:
3.44M
Relative Volume:
10.44
Market Cap:
$586.93M
Revenue:
$14.02M
Net Income/Loss:
$-84.03M
P/E Ratio:
-5.5816
EPS:
-1.47
Net Cash Flow:
$-125.54M
1W Performance:
+25.70%
1M Performance:
+23.03%
6M Performance:
+91.06%
1Y Performance:
+27.87%
1-Day Range:
$7.4001
$8.49
1-Week Range:
$5.77
$8.49
52-Week Range:
$3.85
$8.49
Meiragtx Holdings Plc Stock (MGTX) Company Profile
Name
Meiragtx Holdings Plc
Sector
Industry
Phone
646-860-7985
Address
450 EAST 29TH STREET, NEW YORK, NY
Compare MGTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGTX
Meiragtx Holdings Plc
|
8.12 | 586.93M | 14.02M | -84.03M | -125.54M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.43 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.83 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
578.42 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.42 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.40 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Meiragtx Holdings Plc Stock (MGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-24 | Resumed | Chardan Capital Markets | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Sep-15-20 | Resumed | BofA Securities | Buy |
| Sep-03-19 | Initiated | Piper Jaffray | Overweight |
| Feb-27-19 | Reiterated | Chardan Capital Markets | Buy |
| Jul-03-18 | Initiated | Barclays | Overweight |
| Jul-03-18 | Initiated | BofA/Merrill | Buy |
View All
Meiragtx Holdings Plc Stock (MGTX) Latest News
MeiraGTx Holdings PLC reports results for the quarter ended December 31Earnings Summary - TradingView
MeiraGTx Holdings Announces Joint Venture with Hologen - TipRanks
MeiraGTx secures $200 million, forms joint venture for CNS drugs - Investing.com
MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates - The Manila Times
MeiraGTx stock surges on Hologen AI deal - Investing.com India
MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson's Disease and Industrialize MeiraGTx's Proprietary Manufacturing Process - The Manila Times
MeiraGTx and Hologen Limited Announce $200 Million Collaboration and Formation of Hologen Neuro AI Ltd Joint Venture for Parkinson's Disease Development - Nasdaq
Piper Sandler maintains Overweight on MeiraGTx stock, $26 target By Investing.com - Investing.com South Africa
MeiraGTx Holdings PLC expected to post a loss of 56 cents a shareEarnings Preview - TradingView
MeiraGTx Holdings plc (NASDAQ:MGTX) Shares Purchased by Rhumbline Advisers - Defense World
MeiraGTx (MGTX) Projected to Post Quarterly Earnings on Thursday - Defense World
(MGTX) Investment Analysis - Stock Traders Daily
2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.
MeiraGTx (NASDAQ:MGTX) Receives "Buy" Rating from Chardan Capital - MarketBeat
MeiraGTx Holdings plc (MGTX) expanding its growth trajectory ahead - SETE News
MeiraGTx’s (MGTX) Buy Rating Reaffirmed at Chardan Capital - Defense World
MeiraGTx (NASDAQ:MGTX) Reaches New 52-Week High – What’s Next? - Defense World
MeiraGTx rises after publication of positive data from gene therapy trial for eye disorder - Seeking Alpha
Meiragtx’s gene therapy shows ‘exceptional’ data for blind children - BioWorld Online
MGTX stock soars to 52-week high, reaching $7.39 - Investing.com
MGTX stock soars to 52-week high, reaching $7.39 By Investing.com - Investing.com Canada
MeiraGTx To Advance Gene Therapy For LCA4 Retinal Dystrophy With Positive Phase I/II Results - Nasdaq
MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy - The Manila Times
MeiraGTx Announces Positive Results from First-in-Human Study of Gene Therapy for AIPL1-Related Retinal Dystrophy in Young Children - Nasdaq
Revolutionary Gene Therapy Transforms Children's Vision: The Lancet Validates 100% Success Rate - StockTitan
Kadmon Announces Sale of 1.4 Million Shares of MeiraGTx Holdings plc - ACCESS Newswire
Janney Montgomery Scott LLC Purchases New Stake in MeiraGTx Holdings plc (NASDAQ:MGTX) - MarketBeat
Objective long/short (MGTX) Report - Stock Traders Daily
MeiraGTx (NASDAQ:MGTX) Shares Up 8.6%What's Next? - MarketBeat
Strong week for MeiraGTx Holdings (NASDAQ:MGTX) shareholders doesn't alleviate pain of five-year loss - Simply Wall St
MeiraGTx Holdings plc's (NASDAQ:MGTX) top owners are private equity firms with 25% stake, while 21% is held by institutions - Yahoo Finance
MeiraGTx receives rare pediatric disease designation from FDA for its eye disease treatment - MSN
MeiraGTx Holdings plc (NASDAQ:MGTX) Shares Purchased by JPMorgan Chase & Co. - Defense World
MeiraGTx wins RPD designation for Leber candidate - The Pharma Letter
MeiraGTX CFO Richard Giroux sells $150,960 in ordinary shares - MSN
MeiraGTx Holdings plc (NASDAQ:MGTX) CFO Richard Giroux Sells 24,000 Shares - MarketBeat
MeiraGTx: 2 Possible Near-Term BLA Filings Could Ignite Shareholder Value (NASDAQ:MGTX) - Seeking Alpha
MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis Due to GUCY2D Mutations - Marketscreener.com
MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations - The Manila Times
MeiraGTx Secures Fourth FDA Rare Pediatric Disease Designation for Gene Therapy Treatment - StockTitan
MeiraGTX CFO Richard Giroux sells $150,960 in ordinary shares By Investing.com - Investing.com South Africa
Long Term Trading Analysis for (MGTX) - Stock Traders Daily
Is MeiraGTx Holdings plc (MGTX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Insider Monkey
Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks - Insider Monkey
MeiraGTx (NASDAQ:MGTX) Trading 8% HigherWhat's Next? - MarketBeat
Barclays PLC Acquires 76,437 Shares of MeiraGTx Holdings plc (NASDAQ:MGTX) - Defense World
MeiraGTx Holdings plc (NASDAQ:MGTX) Shares Acquired by Barclays PLC - MarketBeat
MeiraGTx Holdings plc (NASDAQ:MGTX) Shares Sold by Jane Street Group LLC - Defense World
Contrasting Innate Pharma (OTCMKTS:IPHYF) and MeiraGTx (NASDAQ:MGTX) - Defense World
MeiraGTx Holdings plc (NASDAQ:MGTX) CEO Sells $231,878.33 in Stock - MarketBeat
MeiraGTX president sells shares worth $305,342 By Investing.com - Investing.com Nigeria
Meiragtx Holdings Plc Stock (MGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):